Champions Oncology Stock Performance
| CSBR Stock | USD 4.32 0.23 5.05% |
The firm shows a Beta (market volatility) of -0.24, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Champions Oncology are expected to decrease at a much lower rate. During the bear market, Champions Oncology is likely to outperform the market. Champions Oncology right now shows a risk of 4.43%. Please confirm Champions Oncology coefficient of variation, semi variance, price action indicator, as well as the relationship between the treynor ratio and daily balance of power , to decide if Champions Oncology will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Champions Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable fundamental drivers, Champions Oncology is not utilizing all of its potentials. The recent stock price agitation, may contribute to short-term losses for the retail investors. ...more
Actual Historical Performance (%)
Five Day Return (3.59) | Year To Date Return (25.73) | Ten Year Return (42.20) | All Time Return (40.28) |
Last Split Factor 1:12 | Last Split Date 2015-08-12 |
1 | Curis to Release Second Quarter 2023 Financial Results and Hold Conference Call on August 3, 2023 - Quantisnow | 08/28/2024 |
2 | Champions Oncology to Announce First Quarter Financial Results on Wednesday, September 11, 2024 - StockTitan | 09/09/2024 |
3 | Champions Oncology Non-GAAP EPS of 0.11 beats by 0.14, revenue of 14.06M beats by 0.83M | 09/11/2024 |
4 | Champions Oncology upgraded to buy by Craig-Hallum | 09/12/2024 |
5 | Acquisition by Brady Davis of 135000 shares of Champions Oncology at 6.5 subject to Rule 16b-3 | 09/18/2024 |
6 | Disposition of 8333 shares by Sidransky David of Champions Oncology at 3.21 subject to Rule 16b-3 | 09/23/2024 |
7 | Acquisition by Brady Davis of 68000 shares of Champions Oncology at 6.5 subject to Rule 16b-3 | 10/04/2024 |
8 | Acquisition by Ackerman Joel of 124232 shares of Champions Oncology at 5.76 subject to Rule 16b-3 | 10/11/2024 |
9 | Companies Like Champions Oncology Can Afford To Invest In Growth | 10/24/2024 |
10 | Disposition of 88470 shares by Ackerman Joel of Champions Oncology at 2.1 subject to Rule 16b-3 | 10/31/2024 |
11 | Acquisition by Ackerman Joel of 43190 shares of Champions Oncology at 4.64 subject to Rule 16b-3 | 11/12/2024 |
| Begin Period Cash Flow | 10.1 M |
Champions |
Champions Oncology Relative Risk vs. Return Landscape
If you would invest 452.00 in Champions Oncology on August 24, 2024 and sell it today you would lose (20.00) from holding Champions Oncology or give up 4.42% of portfolio value over 90 days. Champions Oncology is currently generating 0.0231% in daily expected returns and assumes 4.4344% risk (volatility on return distribution) over the 90 days horizon. In different words, 39% of stocks are less volatile than Champions, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Champions Oncology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Champions Oncology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Champions Oncology, and traders can use it to determine the average amount a Champions Oncology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0052
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CSBR |
Estimated Market Risk
| 4.43 actual daily | 39 61% of assets are more volatile |
Expected Return
| 0.02 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Champions Oncology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Champions Oncology by adding Champions Oncology to a well-diversified portfolio.
Champions Oncology Fundamentals Growth
Champions Stock prices reflect investors' perceptions of the future prospects and financial health of Champions Oncology, and Champions Oncology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Champions Stock performance.
| Return On Equity | -4.32 | ||||
| Return On Asset | -0.0693 | ||||
| Profit Margin | (0.07) % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 62.94 M | ||||
| Shares Outstanding | 13.59 M | ||||
| Price To Earning | 220.00 X | ||||
| Price To Book | 6.77 X | ||||
| Price To Sales | 1.12 X | ||||
| Revenue | 50.16 M | ||||
| Gross Profit | 24.34 M | ||||
| EBITDA | (5.05 M) | ||||
| Net Income | (7.28 M) | ||||
| Cash And Equivalents | 8.06 M | ||||
| Cash Per Share | 0.60 X | ||||
| Total Debt | 7.43 M | ||||
| Debt To Equity | 1.03 % | ||||
| Current Ratio | 1.11 X | ||||
| Book Value Per Share | (0.02) X | ||||
| Cash Flow From Operations | (6.14 M) | ||||
| Earnings Per Share | (0.26) X | ||||
| Market Capitalization | 58.05 M | ||||
| Total Asset | 26.13 M | ||||
| Retained Earnings | (84.59 M) | ||||
| Working Capital | (7.9 M) | ||||
| Current Asset | 4.34 M | ||||
| Current Liabilities | 5.31 M | ||||
About Champions Oncology Performance
Assessing Champions Oncology's fundamental ratios provides investors with valuable insights into Champions Oncology's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Champions Oncology is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.28) | (0.30) | |
| Return On Capital Employed | (1.60) | (1.68) | |
| Return On Assets | (0.28) | (0.29) | |
| Return On Equity | 3.82 | 4.01 |
Things to note about Champions Oncology performance evaluation
Checking the ongoing alerts about Champions Oncology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Champions Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Champions Oncology had very high historical volatility over the last 90 days | |
| The company reported the previous year's revenue of 50.16 M. Net Loss for the year was (7.28 M) with profit before overhead, payroll, taxes, and interest of 24.34 M. | |
| Champions Oncology currently holds about 8.06 M in cash with (6.14 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.6. | |
| Roughly 26.0% of the company shares are held by company insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Ackerman Joel of 43190 shares of Champions Oncology at 4.64 subject to Rule 16b-3 |
- Analyzing Champions Oncology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Champions Oncology's stock is overvalued or undervalued compared to its peers.
- Examining Champions Oncology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Champions Oncology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Champions Oncology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Champions Oncology's stock. These opinions can provide insight into Champions Oncology's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Champions Stock Analysis
When running Champions Oncology's price analysis, check to measure Champions Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Champions Oncology is operating at the current time. Most of Champions Oncology's value examination focuses on studying past and present price action to predict the probability of Champions Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Champions Oncology's price. Additionally, you may evaluate how the addition of Champions Oncology to your portfolios can decrease your overall portfolio volatility.